Monday, November 16, 2026 Never miss a recall or a rule change Get the free brief →
Inside MedSpa
FDA Recall & Compliance Alerts for Medspa Owners
Business & M&AInMode Q3 revenue holds near $92.1M, margins slip3 days agoRegulatoryJudge bars Medicare price for Botox over plasma rulelast weekRegulatoryMexico approves Restylane Shaype for jawline first3 days agoBusiness & M&AEvolus posts Q3 loss of $0.09, revenue tops estimateslast weekBusiness & M&ACoty shareholders approve 50M-share equity plan boost4 days agoMarketAllergan posts nine ASDS abstracts, two on GLP-1 patientslast weekDevices & TechConexeu's first human collagen batch meets its own specs5 days agoBusiness & M&AGalderma lifts 2026 sales outlook to 22.5-23.5%last weekBusiness & M&AMedytox Q3 operating profit up 74.5% on toxin sales5 days agoBusiness & M&ACytrellis Brings ellacor into UM Nurse Practitioner Courselast weekRegulatoryTrifluent recalls Tridacaine III lidocaine patch6 days agoRegulatoryFDA clears Shenzhen Bway red/NIR LED face mask6 days ago
Devices & Tech

Conexeu's first human collagen batch meets its own specs

A preclinical-stage device company says its first in-house human type I collagen batch passed internal tests, but nobody outside the company has checked the data.

Close-up of a laser engraving machine working indoors with blue light reflection.
Photo: Opt Lasers from Poland / Pexels

Get the free Inside MedSpa brief by email

The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.

Primary document: Weight-loss-related revenue for aesthetic providers may reach about $2 billion by 2030. · Published: 2026-11-10

Conexeu Sciences (NASDAQ: CNXU) said on November 10, 2026, that it has started a human collagen program at its Vancouver research and development facility, and that its first pilot batch of human type I collagen met the company's own specifications. The announcement, in a company press release carried by Stock Titan, pitches the work at aging patients and people who have lost soft tissue after GLP-1 weight loss. Read it as a corporate milestone, not a validated product step.

Free alerts

Free: recall & rule-change alerts for your practice.

Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.

The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.

The pilot-batch testing was internal, unpublished and not independently verified.

What changed

The pilot batch passed identity and structure checks the company set for itself. Those checks covered the protein pattern that type I collagen should show, along with fibril formation, which is the self-assembly step that comes before a gel forms. The company cites "supporting data is on file" and does not publish the numbers.

Conexeu also says its CXU formula, made with human collagen from third-party sources, met objectives in its 12-month P.R.O.O.F. preclinical study. The study used a small-volume injectable model and a 200cc-equivalent large-volume model. Those are animal-model results, and the release says full results are being prepared for peer-reviewed publication. None of that has been published yet.

The company targets a first-quarter 2027 FDA 510(k) submission for its lead device candidate, Ten Minute Tissue. Wound care is named as the first commercial indication, and only if FDA clears the device. The release says any CXU product made with human collagen would need its own separate review.

What it means for practices

Here is the part that matters to an owner. Nothing in this release is a product you can buy, and nothing in it changes what you can inject next quarter. The human collagen described is a development-stage material that is not part of any device submitted to FDA. Conexeu itself says so.

The market pitch is where the numbers get loud. The release cites Boston Consulting Group, which projects GLP-1-related aesthetic provider revenue rising from about $0.7 billion in 2025 to $2.0 billion by 2030. That figure is the one in the headline. It is a third-party forecast, and the company is using it to frame its own opportunity. Treat it as a reason to watch the category, not as a demand number for any single product.

The company also draws a line between its scaffold and existing fillers. Conexeu says CXU is meant to be a temporary scaffold that the body remodels, rather than a volume product. That is a claim about mechanism and design. The release offers no clinical data in humans to back it.

What owners can do

If you are evaluating tissue-restoration products for GLP-1 patients, there is nothing to order from Conexeu now. Ask any vendor for the regulatory status of each product in writing, and ask which FDA pathway it sits on. Ask whether the claim you are hearing is for a cleared indication, an investigational use, or a preclinical result.

Check the animal-model language closely. The release says P.R.O.O.F. is a preclinical, animal-model study, and that preclinical results are not necessarily predictive of human results. If a rep describes those objectives as clinical benefit, that is a gap in the record.

Watch for the peer-reviewed paper. Once the full P.R.O.O.F. data and the characterization data are public, you can compare the injectability and volume results against the company's own predefined benchmarks. Until then, the benchmarks are the company's, not an outside yardstick.

What we don't know yet

The release does not publish the pilot-batch characterization data. It does not say how many batches were made, how the third-party collagen compares to the in-house material, or what the sterility and scale-up results look like. It mentions "sterile processing" only in its forward-looking statements section, with no results.

The 510(k) timing is a target, not a filing. The company says the submission depends on testing, manufacturing and regulatory documentation that are still in progress. Ten Minute Tissue is an investigational device. FDA has not cleared or approved it.

Conexeu's own release says the market estimates it cites may prove inaccurate or may not reflect its addressable market. Read the headline number with that caveat attached.

Business information, not medical or legal advice. Verify regulatory status at FDA.gov.

Source: original report ↗

Business information, not medical or legal advice. Verify product status at FDA.gov.

Free alerts

Free: recall & rule-change alerts for your practice.

Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.

The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.

Share

https://insidemedspa.com/article/conexeu-first-human-collagen-batch-meets-own-specs/

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Inside MedSpa · Free brief

    By the time it's news, it's too late.

    FDA decisions, recalls and the rules you operate under, drafted from the source documents and sent free by email.

    Get the free brief The free Inside MedSpa brief · no card · unsubscribe anytime.
    FDA, recalls and rule changes for practice owners Get the free brief →